Unlocking the power of tolerance to treat autoimmune disease

At Tolagen, we are pioneering a novel class of oral tolerogenic therapies designed to restore immune homeostasis and transform the treatment of chronic inflammatory and autoimmune diseases.

Learn More

A Breakthrough in Immunotherapy

Using synthetic bacteria-inspired nanoparticles, we’re developing first-in-class treatments that safely engage APCs to promote immune tolerance.   

Our approach is designed to be:

Orally administered

Increasing patient compliance and safety

Orally administered

Increasing patient compliance and safety

Orally administered

Increasing patient compliance and safety

Highly targeted

Avoiding systemic side effects seen in traditional therapies

Highly targeted

Avoiding systemic side effects seen in traditional therapies

Highly targeted

Avoiding systemic side effects seen in traditional therapies

Cost-effective

Reducing production costs compared to biologics and cell therapies

Cost-effective

Reducing production costs compared to biologics and cell therapies

Cost-effective

Reducing production costs compared to biologics and cell therapies

Transforming autoimmune disease treatment from management to remission at the root of dysregulation

We are addressing some of the most urgent unmet needs in immunology.

first-in-class

targeting

celiac disease

Our lead candidate, TLG307, aims to provide the first disease-modifying treatment for gluten intolerance.

Market Potential:

$35B

first-in-class

targeting

celiac disease

Our lead candidate, TLG307, aims to provide the first disease-modifying treatment for gluten intolerance.

Market Potential:

$35B

first-in-class

targeting

celiac disease

Our lead candidate, TLG307, aims to provide the first disease-modifying treatment for gluten intolerance.

Market Potential:

$35B

first-in-class

targeting

type 1 diabetes

Our TLG402 seeks to halt the autoimmune attack on pancreatic cells before full disease onset.

Market Potential:

$25B

first-in-class

targeting

type 1 diabetes

Our TLG402 seeks to halt the autoimmune attack on pancreatic cells before full disease onset.

Market Potential:

$25B

first-in-class

targeting

type 1 diabetes

Our TLG402 seeks to halt the autoimmune attack on pancreatic cells before full disease onset.

Market Potential:

$25B

first-in-class

targeting

Inflammatory Bowel Disease

Our lead candidate, TLG307, aims to provide the first disease-modifying treatment for gluten intolerance.

Market Potential:

$16B

first-in-class

targeting

Inflammatory Bowel Disease

Our lead candidate, TLG307, aims to provide the first disease-modifying treatment for gluten intolerance.

Market Potential:

$16B

first-in-class

targeting

Inflammatory Bowel Disease

Our lead candidate, TLG307, aims to provide the first disease-modifying treatment for gluten intolerance.

Market Potential:

$16B

Academic Partners

Andreas Vogt, PhD

PhD in Pharmaceutical Chemistry

Andreas Vogt, PhD

PhD in Pharmaceutical Chemistry

Andreas Vogt, PhD

PhD in Pharmaceutical Chemistry

Kevin Mollen, MD

Chief, Division of Pediatric Surgery

Kevin Mollen, MD

Chief, Division of Pediatric Surgery

Kevin Mollen, MD

Chief, Division of Pediatric Surgery

Mark Schurdak, PhD

Research Associate Professor

Mark Schurdak, PhD

Research Associate Professor

Mark Schurdak, PhD

Research Associate Professor

Jon Piganelli, PhD

Professor of Medicine

Jon Piganelli, PhD

Professor of Medicine

Jon Piganelli, PhD

Professor of Medicine

Backed by Science, Powered by Innovation

Tolagen is supported by leading research institutions and has secured $1.5M in NIH SBIR grants for platform validation and in vivo proof-of-concept studies. As we advance, we are seeking angel investors to propel our pipeline toward Phase 1 clinical trials.

Be Part of the Future of Immune Health

We are on track to initiate Phase 1 trials by 2029, setting the stage for strategic partnerships, further funding rounds, and a path toward IPO.

Learn More

A Game-Changing Approach

Our orally administered, APC-targeting nanomedicines are designed for higher safety, better patient compliance, and lower costs than biologics or cell therapies.

A Game-Changing Approach

Our orally administered, APC-targeting nanomedicines are designed for higher safety, better patient compliance, and lower costs than biologics or cell therapies.

A Game-Changing Approach

Our orally administered, APC-targeting nanomedicines are designed for higher safety, better patient compliance, and lower costs than biologics or cell therapies.

High-Value Market Potential

With Celiac Disease, Inflammatory Bowel Disease, and Type 1 Diabetes as initial targets, our pipeline has blockbuster potential in autoimmune care.

High-Value Market Potential

With Celiac Disease, Inflammatory Bowel Disease, and Type 1 Diabetes as initial targets, our pipeline has blockbuster potential in autoimmune care.

High-Value Market Potential

With Celiac Disease, Inflammatory Bowel Disease, and Type 1 Diabetes as initial targets, our pipeline has blockbuster potential in autoimmune care.

Strong Early-Stage Support

Backed by $1.5M in NIH SBIR funding, we’ve already validated our platform in preclinical models and are preparing for IND-enabling studies.

Strong Early-Stage Support

Backed by $1.5M in NIH SBIR funding, we’ve already validated our platform in preclinical models and are preparing for IND-enabling studies.

Strong Early-Stage Support

Backed by $1.5M in NIH SBIR funding, we’ve already validated our platform in preclinical models and are preparing for IND-enabling studies.

2025